-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Frank D'Amelio (Frank D'Amelio) is a legend in the industry that has received much attention
It is understood that Pfizer Chief Executive Officer (CEO) Albert Bourla has begun to look for D'Amelio's successor externally, and D'Amelio will also stay as a consultant during the transition period
In 2007, D'Amelio joined Pfizer in 2007 after holding operations and finance positions at AT&T and Lucent Technologies in the telecommunications industry for nearly three years
After two years in office, he led Pfizer to acquire Wyeth for US$68 billion, obtaining the blockbuster "Prevaler" vaccine and a leading vaccine platform
D'Amelio is known in the industry for cutting business and focusing on key areas
According to Bourla, when the new crown epidemic hit, D'Amelio was mainly responsible for overseeing Pfizer's manufacturing supply chain and helping to lead the team through the most challenging period
"Frank has left an indelible feat at Pfizer.
D'Amelio is a very successful leader and has been on the top CFO list of Institutional Investor magazine for 10 consecutive years
According to public information: D'Amelio was born in Hoboken, New Jersey.
Later, he went to St.
In 1996, when Lucent was spun off from AT&T, D'Amelio served as Lucent’s CFO and led the company to complete a record IPO in the same year
In 2007, D'Amelio joined Pfizer as CFO
To fill D'Amelio's role in the supply chain, Bourla hired 18-year Pfizer veteran Mike McDermott as executive vice president and chief global supply officer
Under his initiative, Pfizer plans to produce 3 billion doses of the new crown vaccine this year and another 4 billion doses next year
Who will be the new CFO candidate for this "universal pharmaceutical factory"?
Note: The original text has been deleted